Not only did more tumor infiltrating CD8+ T-cells in LL-37DC treated tumors express the activation markers CD44 and PD1, but we also observed an increase in the expression level of PD1 on these CD8+ T-cells. The gene discussed is CD44; the disease is neoplasm.